LENEXA, Kan.--(BUSINESS WIRE)--CyDex Pharmaceuticals, Inc. today announced that it has received orphan-drug designation from the U.S. Food and Drug Administration (FDA) for melphalan “as a high-dose conditioning treatment prior to hematopoietic progenitor (stem) cell transplantation.”
